When exposed to a hyperglycemic milieu, the GIPR was found to downregulate in a study of pancreatic islet cells (59) and the patients with T2DM might express a small amount of GIPR or defective GIPR (60, 61)
The result is a medication that helps people consume less and burn more energy while also balancing blood sugar and supporting breakdown of fat, which is why it has shown greater weight loss in early studies, says Rhodes
The GLP-1 Access Gap: Mapping Who Can Actually Afford Americas Miracle Weight-Loss Drugs, The Health Management Academy, February 4, 2026, Virta internal analysis of commercially enrolled population enrolled since Q2 2025 McKenzie, A.L., Athinarayanan, S.J
Between ages 35 and 55, women experience a gradual decline in estrogen production